Sartorius Stedim Biotech SA Price, Chart & Factor Exposure
Free Data & Analytics AccessNext earnings: Tue, Feb 23, 2027, after the market closes · estimates and history
Sartorius Stedim Biotech SA Forecast
Sartorius Stedim Biotech SA short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 33.9% a year, a typical one-standard-deviation range is 213.48–234.92 over a week, 202.24–246.16 over a month and 148.12–300.28 over a year. (Signals as of 5 Nov 2026.)
Sartorius Stedim Biotech SA Price Chart
Sartorius Stedim Biotech SA Factors
YoY −3.9%
YoY +13.6%
YoY +8.8%
YoY +3.5%
YoY +11.1%
YoY −2.3%
YoY +4.0%
YoY +18.0%
YoY −5.6%
YoY −15.3%
YoY +15.7%
YoY +12.6%
YoY +16.3%
YoY −16.9%
YoY 0.0%
YoY +19.9%
Sartorius Stedim Biotech SA fundamentals: income statement, balance sheet & cash flow
Sartorius Stedim Biotech SA reported revenue of €2.97bn and net income of €265.6m in FY2025, the year ended 31 December 2025 — revenue up 6.7% and net income up 51.7% on the prior year. Free cash flow was €145.4m. These figures are as reported in the filings, not restated: 21 fiscal years and 59 quarters of history, back to December 2005.
| EUR millions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 2,967.5 | 2,780.0 | 2,775.5 | 3,492.7 | 2,887.0 |
| Cost of revenue | 1,622.2 | 1,573.3 | 1,542.0 | 1,658.2 | 1,334.0 |
| Gross profit | 1,345.3 | 1,206.7 | 1,233.5 | 1,817.4 | 1,553.0 |
| Research & development | 132.6 | 144.1 | 129.5 | 132.4 | 110.5 |
| Selling, general & admin. | 661.3 | 692.0 | 619.5 | — | 529.8 |
| Operating income | 549.0 | 370.6 | 484.5 | 1,101.2 | 912.7 |
| EBITDA | 867.1 | 670.5 | 755.7 | 1,330.7 | 812.0 |
| Interest expense | 152.7 | 158.9 | 121.1 | 41.0 | 23.7 |
| Pre-tax income | 373.2 | 219.2 | 401.1 | 1,130.4 | 646.7 |
| Income tax | 107.3 | 40.7 | 89.0 | 250.5 | 232.4 |
| Net income | 265.6 | 175.1 | 309.7 | 876.1 | 414.4 |
Download Sartorius Stedim Biotech SA fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.DIM.PA&statement=all&freq=a&format=csv&years=10
Figures in EUR, statements as filed. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic.
Research on Sartorius Stedim Biotech SA
Explore MacroFinance macro & markets research and analysis.
Sartorius Stedim Biotech SA Trading Strategies
9 backtested tactical asset allocation strategies hold VGK (European market), the closest tradable exposure to Sartorius Stedim Biotech SA; 1 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in VGK | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Defensive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation - CPR | Moderate | Monthly | Premium · upgrade to view | |||
| Financial Mentor's Optimum3 | Moderate | Monthly | Premium · upgrade to view | |||
| Wouter Keller's Bold Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Protective Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keller and Keuning's Vigilant Asset Allocation - Balanced | Moderate | Monthly | Premium · upgrade to view | |||
| Ilya Kipnis' Defensive Adaptive Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Keuning and Keller's Generalized Protective Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
Statistical Distribution of Returns
PlusHow Sartorius Stedim Biotech SA’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Sartorius Stedim Biotech SA (France)
Sartorius Stedim Biotech SA is a listed security in France. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Sartorius Stedim Biotech SA
Frequently asked questions
What is Sartorius Stedim Biotech SA?
What is the latest Sartorius Stedim Biotech SA price?
Is Sartorius Stedim Biotech SA in an uptrend?
How volatile is Sartorius Stedim Biotech SA?
What factors affect Sartorius Stedim Biotech SA?
Which trading strategies trade Sartorius Stedim Biotech SA?
How are Sartorius Stedim Biotech SA returns analysed?
Where can I download free Sartorius Stedim Biotech SA historical data?
Free Sartorius Stedim Biotech SA historical data (last 10 years)
Browse or instantly download the last 10 years of Sartorius Stedim Biotech SA daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.DIM.PA&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 220.6 |
| 2026-11-19 | 228.6 |
| 2026-11-18 | 226.8 |
| 2026-11-17 | 224.2 |
| 2026-11-16 | 225.2 |
| 2026-11-13 | 223.2 |
| 2026-11-12 | 222.8 |
| 2026-11-11 | 226.8 |
| 2026-11-10 | 223.4 |
| 2026-11-09 | 226.2 |
About this stock
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.